FDA Homepage
FDA Lapse in Funding
In the absence of either an FY 2019 appropriation or a Continuing Resolution for FDA, beginning on December 22, 2018 and continuing until the date of enactment of an FY 2019 appropriation or Continuing Resolution ("lapse period"), agency operations continue to the extent permitted by law, such as activities necessary to address imminent threats to the safety of human life and activities funded by carryover user fee funds. Read more
News & Events
- December 21, 2018 - FDA permits marketing of a diagnostic test to aid in measuring nutrients in breast milk
- December 21, 2018 - FDA approves new treatment for adult patients with rare, life-threatening blood disease
- December 21, 2018 - FDA approves first treatment for rare blood disease
Newsroom
Recent Consumer Updates
Browse by Audience
-
For Consumers
Updates and information for staying safe and healthy -
For Patients
Learn about other treatments, drug/device approvals, public meetings and more -
For Health Professionals
Medical product safety information, adverse event/problem reporting and more -
For Scientists & Researchers
NCTR, pediatrics, clinical trials, Critical Path Initiative, foods and veterinary medicine research, and more -
For Industry
Guidance, registration and listing, pay user fees, import programs and more
FDA Voices:
Perspectives from FDA Experts
-
December 18, 2018
Our Door Is Open: FDA Puts Patients First
Page Last Updated: 12/21/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English


